再获殊荣！贵州百灵跻身中国医药工业百强榜中药企业30强
7月22日，2019年度中国医药工业百强系列榜单盛大发布。凭借雄厚的研发生产实力和强劲的市场推广能力，贵州百灵企业集团成功入选2019年度中国医药工业百强系列榜单“中国中药企业TOP100排行榜”，位列第30位。该系列榜单是由米内研究院组织中国医药工业百强排行榜专家委员会，依托米内网三大终端六大市场终端格局数据库，聚焦医药工业企业的创新驱动力和专业推广力进行评选。其中，创新驱动力主要从企业研发投入R&D综合指标进行评判；专业推广力则重点根据临床医生和患者的最终选择需求所决定的终端定量数据来刚性定义。
经过多方面综合考量，贵州百灵等榜单决出企业代表着中国中医药行业最高水平，在2019年医药行业整体环境承压较大的情况下，积极促进中医药行业健康平稳发展，为广大中医药企业树立了标杆和榜样，得到了社会和市场的认可。
作为全国最大的苗药研制生产企业，贵州百灵在生产上牢抓质量安全，推广上不断下沉营销渠道，扩大优质药品触达市场。随着多年的市场打造和沉淀，公司已完成全国32个省、市及自治区营销网络的覆盖，积极推进OTC和处方药的市场推广和学术推广工作，强大的渠道管理和终端覆盖成为公司实现销售不断增长的直接动力。
得益于深度下沉的营销网络优势，2019年，公司核心产品表现稳健。明星产品银丹心脑通软胶囊实现销售收入7.61亿元，较上年同期增长10.57%；以小儿柴桂退热颗粒、双羊喉痹通颗粒为代表的颗粒剂产品继续保持快速增长，共计实现销售收入6.6亿元，较上年同期增长16.96%。凭借产品优势和强劲综合实力，贵州百灵荣登“2019年度中国非处方药企业及产品榜”第16位，排名较往年持续上升，同时，贵州百灵咳速停糖浆/胶囊、维C银翘片、小儿柴桂退热颗粒、复方一枝黄花喷雾剂、双羊喉痹通颗粒等8个品种强势上榜，市占率持续提升，品牌影响力不断增强。
为实现创新驱动发展，贵州百灵一贯重视产品研发工作，将其视为推动自身发展的源动力，通过结合科研院所、高等院校和企业在“产、学、研、用”方面的资源，持续增强公司在药物研发方面的核心竞争力。围绕以民族药、苗药为核心，化学药和生物药为两翼的发展战略，近年来，公司瞄准恶性肿瘤、代谢疾病、感染疾病和临床空白四大领域，持续加大研发投入，不断增强公司产品储备实力，糖宁通络、普依司他、黄连解毒丸等多个重点项目均有序推进。
未来，在国家政策大力支持中医药发展的背景下，贵州百灵将坚持以提升全民健康水平为己任，在不断挖掘和开发经典验方和临床价值高的中成药（民族药）的同时，紧跟国际科研前沿，加强研发创新体系的建设与研发投入，发挥“中国中药企业百强”的示范带动作用，促进中国新时代中医药行业的发展壮大！
{"weixin":{"label":"微信","name":"weixin","selected":true,"value":true,"sortid":"1","shareid":"weixin","sharetitle":"分享到微信","event":"shareToWeiXin","lang":"shareWeb_WeiXin"},"copy":{"label":"复制网址","name":"copy","selected":true,"value":true,"sortid":"2","shareid":"copy","sharetitle":"复制网址","event":"copy_url","lang":"shareWeb_Copy"},"qq":{"label":"QQ好友","name":"qq","selected":true,"value":false,"sortid":"1","shareid":"qq","sharetitle":"分享到QQ","event":"shareToQQ","lang":"shareWeb_QQ"},"sina_weibo":{"label":"新浪微博","name":"sina_weibo","selected":true,"value":true,"sortid":"4","shareid":"sina_weibo","sharetitle":"分享到新浪微博","event":"shareToSinaWB","lang":"shareWeb_SinaWeiBo"},"qq_zone":{"label":"QQ空间","name":"qq_zone","selected":true,"value":true,"sortid":"5","shareid":"qq_zone","sharetitle":"分享到QQ空间","event":"shareToQzone","lang":"shareWeb_QQZone"},"renren":{"label":"人人网","name":"renren","selected":true,"value":true,"sortid":"7","shareid":"renren","sharetitle":"分享到人人网","event":"shareToRenren","lang":"shareWeb_RenRen"},"douban":{"label":"豆瓣网","name":"douban","selected":true,"value":true,"sortid":"8","shareid":"douban","sharetitle":"分享到豆瓣网","event":"shareToDouban","lang":"shareWeb_DouBan"},"baidu_tieba":{"label":"百度贴吧","name":"baidu_tieba","selected":true,"value":true,"sortid":"10","shareid":"baidu_tieba","sharetitle":"分享到百度贴吧","event":"shareToTieba","lang":"shareWeb_TieBa"},"Facebook":{"label":"Facebook","name":"Facebook","selected":true,"value":true,"sortid":"11","shareid":"Facebook","sharetitle":"分享到FaceBook","event":"shareToFacebook","lang":"shareWeb_Facebook"},"Twitter":{"label":"Twitter","name":"Twitter","selected":true,"value":true,"sortid":"12","shareid":"Twitter","sharetitle":"分享到Twitter","event":"shareToTwitter","lang":"shareWeb_Twitter"},"LinkedIn":{"label":"LinkedIn","name":"LinkedIn","selected":true,"value":true,"sortid":"13","shareid":"LinkedIn","sharetitle":"分享到linkedIn","event":"shareToLinkedin","lang":"shareWeb_Linkedin"},"whatsapp":{"label":"whatsapp","name":"whatsapp","selected":true,"value":true,"sortid":"15","shareid":"whatsapp","sharetitle":"分享到whatsapp","event":"shareToWhatsapp","lang":"shareWeb_whatsapp"},"line":{"label":"line","name":"line","selected":true,"value":true,"sortid":"15","shareid":"line","sharetitle":"分享到line","event":"shareToLine","lang":"shareWeb_line"},"qq_weibo":{"label":"腾讯微博","name":"qq_weibo","selected":true,"value":true,"sortid":"3","shareid":"qq_weibo","sharetitle":"分享到腾讯微博","event":"shareToQQwb","lang":"shareWeb_QQWeiBo"},"peopleBlog":{"label":"人民微博","name":"propleBlog","selected":true,"value":true,"sortid":"14","shareid":"propleBlog","sharetitle":"分享到人民微博","event":"shareToPeopleBlog","lang":"shareWeb_peopleBlog"}}
